Literature DB >> 16740706

Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors.

Jelena Krneta1, Jens Kroll, Frauke Alves, Claudia Prahst, Farahnaz Sananbenesi, Christian Dullin, Sarah Kimmina, David J Phillips, Hellmut G Augustin.   

Abstract

The transforming growth factor-beta superfamily member activin and its antagonist, follistatin, act as a pleiotropic growth factor system that controls cell proliferation, differentiation, and apoptosis. Activin inhibits fibroblast growth factor 2-induced sprouting angiogenesis in vitro (spheroidal angiogenesis assay) and in vivo (Matrigel assay). To further study the role of the activin/follistatin system during angiogenesis and tumor progression, activin- and follistatin-expressing R30C mammary carcinoma cells were studied in mouse tumor experiments. Surprisingly, activin-expressing tumors grew much faster than follistatin-expressing tumors although they failed to induce increased angiogenesis (as evidenced by low microvessel density counts). Conversely, follistatin-expressing tumors were much smaller but had a dense network of small-diameter capillaries. Qualitative angioarchitectural analyses (mural cell recruitment, perfusion) revealed no major functional differences of the tumor neovasculature. Analysis of activin- and follistatin-expressing R30C cells identified a cell autonomous role of this system in controlling tumor cell growth. Whereas proliferation of R30C cells was not altered, follistatin-expressing R30C cells had an enhanced susceptibility to undergo apoptosis. These findings in experimental tumors are complemented by an intriguing case report of a human renal cell carcinoma that similarly shows a dissociation of angiogenesis and tumorigenesis during tumor progression. Collectively, the data shed further light into the dichotomous stimulating and inhibiting roles that the activin/follistatin system can exert during angiogenesis and tumor progression. Furthermore, the experiments provide a critical proof-of-principle example for the dissociation of angiogenesis and tumorigenesis, supporting the concept that tumor growth may not be dependent on increased angiogenesis as long as a minimal intratumoral microvessel density is maintained.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16740706     DOI: 10.1158/0008-5472.CAN-05-3821

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

Review 1.  The role of activin in mammary gland development and oncogenesis.

Authors:  Karen A Dunphy; Alan L Schneyer; Mary J Hagen; D Joseph Jerry
Journal:  J Mammary Gland Biol Neoplasia       Date:  2011-04-08       Impact factor: 2.673

2.  Evaluation of annexin A2 and as potential biomarkers for hepatocellular carcinoma.

Authors:  Nevine El-Abd; Amal Fawzy; Tamer Elbaz; Sherif Hamdy
Journal:  Tumour Biol       Date:  2015-07-20

3.  Serum follistatin in patients with prostate cancer metastatic to the bone.

Authors:  Francesca Maria Tumminello; Giuseppe Badalamenti; Fabio Fulfaro; Lorena Incorvaia; Marilena Crescimanno; Carla Flandina; Maria Vittoria Sepporta; Gaetano Leto
Journal:  Clin Exp Metastasis       Date:  2010-07-11       Impact factor: 5.150

4.  The Local Control of the Pituitary by Activin Signaling and Modulation.

Authors:  Louise M Bilezikjian; Wylie W Vale
Journal:  Open Neuroendocrinol J       Date:  2011-01-01

5.  A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.

Authors:  Grace K Dy; Sumithra J Mandrekar; Garth D Nelson; Jeffrey P Meyers; Araba A Adjei; Helen J Ross; Rafat H Ansari; Alan P Lyss; Philip J Stella; Steven E Schild; Julian R Molina; Alex A Adjei
Journal:  J Thorac Oncol       Date:  2013-01       Impact factor: 15.609

6.  DNA damage drives an activin a-dependent induction of cyclooxygenase-2 in premalignant cells and lesions.

Authors:  Colleen Fordyce; Tim Fessenden; Curtis Pickering; Jason Jung; Veena Singla; Hal Berman; Thea Tlsty
Journal:  Cancer Prev Res (Phila)       Date:  2009-12-22

Review 7.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

8.  Morphologic changes of mammary carcinomas in mice over time as monitored by flat-panel detector volume computed tomography.

Authors:  Jeannine Missbach-Guentner; Christian Dullin; Sarah Kimmina; Marta Zientkowska; Melanie Domeyer-Missbach; Cordula Malz; Eckhardt Grabbe; Walter Stühmer; Frauke Alves
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

9.  Identification of proteins involved in neural progenitor cell targeting of gliomas.

Authors:  Karin Staflin; Thole Zuchner; Gabriella Honeth; Anna Darabi; Cecilia Lundberg
Journal:  BMC Cancer       Date:  2009-06-26       Impact factor: 4.430

10.  Differential expression of follistatin and FLRG in human breast proliferative disorders.

Authors:  Enrrico Bloise; Henrique L Couto; Lauretta Massai; Pasquapina Ciarmela; Marzia Mencarelli; Lavinia E Borges; Michela Muscettola; Giovanni Grasso; Vania F Amaral; Geovanni D Cassali; Felice Petraglia; Fernando M Reis
Journal:  BMC Cancer       Date:  2009-09-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.